Navigation Links
Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Date:9/7/2011

WORCESTER, Mass. and TORONTO, Sept. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that Mark Fletcher, the Company's President & Chief Executive Officer, and Dr. Eric von Hofe, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) will make a Generex/Antigen presentation at  the Rodman & Renshaw 13th Annual Healthcare Conference.  The presentation will take place at 4:45 pm ET on September 12, 2011 in the Starlight North room at the Waldorf Astoria Hotel in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
2. Generex Provides Corporate Update
3. Generex Provides Preliminary Results of Generex Oral-lyn™ Clinical Trials in Patients with Type 1 Diabetes and Patients with Impaired Glucose Tolerance
4. Generex Announces Appointment of CEO for Post-Spinout Antigen Express
5. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
6. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
7. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
8. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
9. Generex Launches New Corporate Website
10. Generex Unveils Strategic Development Plan
11. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited ... their Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal ... are the first office to be chosen by the dental implant manufacturer, Straumann, to ...
(Date:2/12/2016)... ... 12, 2016 , ... Nearly every health website and vision ... articles generally list between five and 15 foods that should be consumed regularly ... of these lists and believes that nutritious eye healthy foods are extremely important, ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... the real facts surrounding all those Bible stories. For generations families have gathered to ... Yisrayl says there is more to these than just mere “stories”. , The ...
(Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the ... licensed under Dignity Health Arizona General Hospital , which opened last year in ... our new freestanding emergency room delivers the highest quality care to Mesa and the ...
Breaking Medicine News(10 mins):